Gene variant shapes beta-blocker’s effectiveness

A medication widely used for heart failure may be most effective in people who have a common variant of a particular gene, a laboratory study suggests. Genetic testing for the variant could potentially identify patients who are most likely to benefit from the drug carvedilol, the researchers say.

Beta-blocking drugs such as carvedilol reduce the heart’s workload by blocking beta-adrenergic receptors on cells.